<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial assessment and management of acute stroke</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial assessment and management of acute stroke</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial assessment and management of acute stroke</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jamary Oliveira-Filho, MD, MS, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael T Mullen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan A Edlow, MD, FACEP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The subacute and long-term assessment and management of patients who have suffered a stroke includes physical therapy and testing to determine the precise etiology of the event so as to prevent recurrence. The acute management differs. Immediate goals include minimizing brain injury, treating medical complications, and moving toward uncovering the pathophysiologic basis of the patient's symptoms.</p><p>Patient assessment and management during the acute phase (first few hours) of an ischemic stroke will be reviewed here. Use of thrombolytic therapy, endovascular thrombectomy, treatment of patients not eligible for reperfusion therapy, the clinical diagnosis of various types of stroke, and the subacute and long-term assessment of patients who have had a stroke are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a> and  <a class="medical medical_review" href="/z/d/html/1134.html" rel="external">"Clinical diagnosis of stroke subtypes"</a> and  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INITIAL ASSESSMENT</span><span class="headingEndMark"> — </span>Sudden loss of focal brain function is the core feature of the onset of ischemic stroke. However, patients with conditions other than brain ischemia may present in a similar fashion  (<a class="graphic graphic_table graphicRef69869" href="/z/d/graphic/69869.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">"Differential diagnosis of transient ischemic attack and acute stroke"</a>.)</p><p>In addition, patients suffering a stroke may present with other serious medical conditions. Thus, the initial evaluation requires a rapid but broad assessment.</p><p>The goals in the initial phase include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ensuring medical stability, with particular attention to airway, breathing, and circulation</p><p class="bulletIndent1"><span class="glyph">●</span>Quickly reversing any conditions that are contributing to the patient's problem</p><p class="bulletIndent1"><span class="glyph">●</span>Determining if patients with acute ischemic stroke are candidates for intravenous thrombolytic therapy  (<a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">table 2</a>) or endovascular thrombectomy (see  <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Moving toward uncovering the pathophysiologic basis of the patient's neurologic symptoms</p><p></p><p>Time is of the essence in the hyperacute evaluation of stroke patients. The history, physical examination, serum glucose, oxygen saturation, and a noncontrast computed tomography (CT) scan are sufficient in most cases to guide acute therapy (see <a class="local">'Immediate laboratory studies'</a> below). Other tests are considered based upon individual patient characteristics, but the absence or unavailability of any additional tests need not be a reason to delay therapy if otherwise indicated.</p><p class="headingAnchor" id="H66230911"><span class="h2">Airway, breathing, and circulation</span><span class="headingEndMark"> — </span>Assessing vital signs and ensuring stabilization of airway, breathing, and circulation is part of the initial evaluation of all patients with critical illness, including those with stroke [<a href="#rid1">1</a>]. Patients with decreased consciousness or bulbar dysfunction may be unable to protect their airway, and those with increased intracranial pressure due to hemorrhage, vertebrobasilar ischemia, or bihemispheric ischemia can present with vomiting, decreased respiratory drive, or muscular airway obstruction. Hypoventilation, with a resulting increase in carbon dioxide, may lead to cerebral vasodilation and elevate intracranial pressure.</p><p>In these cases, intubation may be necessary to restore adequate ventilation and to protect the airway from aspiration. Patients with adequate ventilation should have the oxygen saturation monitored. Patients who are hypoxic should receive supplemental oxygen to maintain oxygen saturation &gt;94 percent [<a href="#rid1">1</a>]. Supplemental oxygen should not routinely be given to nonhypoxic patients with acute ischemic stroke.</p><p class="headingAnchor" id="H4"><span class="h2">History and physical</span><span class="headingEndMark"> — </span>Establishing the time of ischemic stroke symptom onset is critical because it is the main determinant of eligibility for treatment with intravenous thrombolysis  (<a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">table 2</a>) and endovascular thrombectomy [<a href="#rid2">2</a>]. For patients who are unable to provide a reliable onset time, symptom onset is defined as the time the patient was last known to be normal or at baseline neurologic status [<a href="#rid1">1</a>]. At times, information from family members, co-workers, or paramedics (who interviewed witnesses to the onset) may establish the time the patient was last known to be normal. For patients presenting within the therapeutic window for intravenous thrombolysis (less than 4.5 hours from symptom onset) or mechanical thrombectomy (less than 24 hours from symptom onset), the history needs to be accurate but rapid; contraindications to thrombolytic treatment should also be assessed  (<a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke", section on 'Rapid evaluation'</a>.)</p><p>The history and physical examination should be used to distinguish between other disorders in the differential diagnosis of brain ischemia  (<a class="graphic graphic_table graphicRef69869" href="/z/d/graphic/69869.html" rel="external">table 1</a>). As examples, seizures, syncope, migraine, hypoglycemia (see <a class="local">'Hypoglycemia'</a> below), hyperglycemia, movement disorders, or drug toxicity can mimic acute ischemia [<a href="#rid1">1,3</a>]. The most difficult cases involve patients with the combination of focal signs and altered level of consciousness. It is important to ask the patient, relative, or any reliable informant whether the patient takes insulin or oral hypoglycemic agents, has a history of epilepsy, drug overdose or abuse, or recent trauma. (See  <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">"Differential diagnosis of transient ischemic attack and acute stroke"</a>.)</p><p>Diagnosing an intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) as soon as possible can be lifesaving [<a href="#rid4">4,5</a>]. The history may be helpful in this regard. The presence of acute onset headache and vomiting favor the diagnosis of ICH or SAH compared with a thromboembolic stroke  (<a class="graphic graphic_figure graphicRef60831" href="/z/d/graphic/60831.html" rel="external">figure 1</a>), while the abrupt onset of impaired cerebral function without focal symptoms favors the diagnosis of SAH. Another important element of the history is whether the patient takes anticoagulant drugs. Even with these clues, diagnosing intracranial hemorrhage on clinical grounds is very imprecise, so early neuroimaging with a CT or magnetic resonance imaging (MRI) scan is critical. CT is preferred at most centers, as it can be obtained very rapidly and is effective at distinguishing between ischemic and hemorrhagic stroke (see  <a class="medical medical_review" href="/z/d/html/1085.html" rel="external">"Neuroimaging of acute stroke"</a>). It is important to assess and stabilize vital physiologic functions <strong>before</strong> sending the patient for an imaging study.</p><p>The physical examination should include careful evaluation of the neck and retroorbital regions for vascular bruits, and palpation of pulses in the neck, arms, and legs to assess for their absence, asymmetry, or irregular rate. The heart should be auscultated for murmurs (see  <a class="medical medical_review" href="/z/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a>). The lungs should be assessed for abnormal breath sounds, bronchospasm, fluid overload, or stridor.</p><p>The skin should be examined for signs of endocarditis, cholesterol emboli, purpura, ecchymoses, or evidence of recent surgery or other invasive procedures, particularly if reliable history is not forthcoming. The funduscopic examination may be helpful if there are cholesterol emboli or papilledema. The head should be examined for signs of trauma. A tongue laceration may suggest a seizure.</p><p>In cases where there is a report or suspicion of a fall, the neck should be immobilized until evaluated radiographically for evidence of serious trauma. Examination of the extremities is important to look for evidence of systemic arterial emboli, distal ischemic, cellulitis, and deep vein thrombosis; the latter should raise the possibility that the patient is receiving anticoagulant treatment.</p><p class="headingAnchor" id="H95636670"><span class="h2">Neurologic evaluation</span><span class="headingEndMark"> — </span>Ischemia in different vascular territories presents with specific syndromes  (<a class="graphic graphic_table graphicRef75487" href="/z/d/graphic/75487.html" rel="external">table 3</a>). The history should focus upon the time of symptom onset, the course of symptoms over time, possible embolic sources, possible recent trauma (which could either represent a contraindication to intravenous thrombolysis or suggest an arterial dissection as a cause), conditions in the differential diagnosis, and concomitant diseases. (See  <a class="medical medical_review" href="/z/d/html/1134.html" rel="external">"Clinical diagnosis of stroke subtypes"</a>.)</p><p>The neurologic examination should attempt to confirm the findings from the history and provide a quantifiable examination for further assessment over time. Many scales are available that provide a structured, quantifiable neurologic examination. One of the most widely used and validated scales is the National Institutes of Health Stroke Scale (NIHSS), composed of 11 items  (<a class="graphic graphic_table graphicRef61698" href="/z/d/graphic/61698.html" rel="external">table 4</a>) adding up to a total score of 0 to 42 (<a class="calc calc_professional" href="/z/d/html/91350.html" rel="external">calculator 1</a>); defined cutpoints for mild, moderate, and severe stroke are not well established, but cut-points of NIHSS score &lt;5 for mild, 5 to 9 for moderate, and ≥10 for severe stroke may be reasonable.</p><p>The three most predictive examination findings for the diagnosis of acute stroke are facial paresis, arm drift/weakness, and abnormal speech (a combination of dysarthria and language items derived from the NIHSS) [<a href="#rid6">6,7</a>]. The NIHSS score on admission has been correlated to stroke outcome  (<a class="graphic graphic_table graphicRef81859" href="/z/d/graphic/81859.html" rel="external">table 5</a>) [<a href="#rid8">8,9</a>], and its use is recommended for all patients with suspected stroke [<a href="#rid10">10</a>]. The NIHSS does not capture all stroke-related impairments, particularly with posterior circulation strokes. (See  <a class="medical medical_review" href="/z/d/html/14084.html" rel="external">"Use and utility of stroke scales and grading systems", section on 'NIHSS'</a>.)</p><p class="headingAnchor" id="H95644450"><span class="h2">Immediate laboratory studies</span><span class="headingEndMark"> — </span>Urgent brain imaging with CT or MRI is mandatory in all patients with sudden neurologic deterioration or acute stroke. (See <a class="local">'Neuroimaging'</a> below.)</p><p>All patients with suspected stroke should have the following studies urgently as part of the acute stroke evaluation [<a href="#rid1">1,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Noncontrast brain CT or brain MRI</p><p class="bulletIndent1"><span class="glyph">●</span>Finger stick blood glucose</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen saturation</p><p></p><p>Other immediate tests for the evaluation of ischemic and hemorrhagic stroke include the following [<a href="#rid1">1,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CT angiography of the head and neck with CT perfusion, or MR angiography with diffusion-weighted imaging (DWI), with or without MR perfusion-weighted imaging (PWI), for patients who may be eligible for mechanical thrombectomy</p><p class="bulletIndent1"><span class="glyph">●</span>MRI with DWI, to identify patients with wake-up stroke or unknown stroke onset time who have lesions that are positive on DWI but negative on fluid-attenuated inversion recovery (FLAIR), suggesting onset within 4.5 hours and eligibility for intravenous thrombolysis</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (this should not delay the noncontrast brain CT)</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count including platelets</p><p class="bulletIndent1"><span class="glyph">●</span>Troponin</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time and international normalized ratio (INR)</p><p class="bulletIndent1"><span class="glyph">●</span>Activated partial thromboplastin time</p><p class="bulletIndent1"><span class="glyph">●</span>Ecarin clotting time, thrombin time, or appropriate direct factor Xa activity assay if known or suspected that the patient is taking direct thrombin inhibitor or direct factor Xa inhibitor and is otherwise a candidate for intravenous thrombolytic therapy</p><p></p><p>However, thrombolytic therapy for acute ischemic stroke (see <a class="local">'Acute therapy'</a> below) should not be delayed while awaiting the results of hematologic studies unless the patient has received anticoagulants or there is suspicion of a bleeding abnormality or thrombocytopenia. The only test that is mandatory before initiation of intravenous thrombolysis is blood glucose [<a href="#rid1">1</a>].</p><p>The following laboratory studies may be appropriate in selected patients [<a href="#rid1">1,4,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes, urea nitrogen, creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Toxicology screen</p><p class="bulletIndent1"><span class="glyph">●</span>Blood alcohol level</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in women of childbearing potential</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial blood gas if hypoxia is suspected</p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph if lung disease is suspected</p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture if subarachnoid hemorrhage is suspected and head CT scan is negative for blood; note that lumbar puncture will preclude administration of intravenous thrombolysis, though thrombolysis should not be given if there is suspicion for subarachnoid hemorrhage as the cause of the symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Electroencephalogram if seizures are suspected</p><p></p><p>Chest radiography, urinalysis and blood cultures are indicated if fever is present. We also suggest blood for type and cross match in case fresh frozen plasma is needed to reverse a coagulopathy if ICH is present. (See  <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>In order to limit medication dosage errors, particularly with the use of intravenous thrombolysis with <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">alteplase</a> or <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">tenecteplase</a>, an accurate body weight should be obtained early during the urgent evaluation [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H95646379"><span class="h3">Neuroimaging</span><span class="headingEndMark"> — </span>In the evaluation of the acute stroke patient, imaging studies are necessary to exclude hemorrhage as a cause of the deficit, and they are useful to assess the degree of brain injury and to identify the vascular lesion responsible for the ischemic deficit. Advanced CT and MRI technologies may be able to distinguish between brain tissue that is irreversibly infarcted and that which is potentially salvageable, thereby allowing better selection of patients who are likely to benefit from therapy. This topic is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1085.html" rel="external">"Neuroimaging of acute stroke"</a>.)</p><p class="headingAnchor" id="H95646729"><span class="h3">Cardiac studies</span><span class="headingEndMark"> — </span>Electrocardiography (ECG) is important for detecting signs of concomitant acute cardiac ischemia. This test is particularly important in the setting of stroke, as patients with ischemic stroke frequently harbor coronary artery disease but may not be able to report chest pain.</p><p>Stroke alone can be associated with ECG changes. The sympathetic response to stroke can lead to demand-induced myocardial ischemia. In large strokes, especially subarachnoid hemorrhage, there are centrally mediated changes in the ECG.</p><p>The ECG and cardiac monitoring are important for the detection of chronic or intermittent arrhythmias that predispose to embolic events (eg, atrial fibrillation) and for detecting indirect evidence of atrial/ventricular enlargement that may predispose to thrombus formation. Current guidelines recommend cardiac monitoring for at least the first 24 hours after the onset of ischemic stroke to look for atrial fibrillation (AF) or atrial flutter [<a href="#rid1">1</a>]. However, paroxysmal AF may be undetected on standard cardiac monitoring such as continuous telemetry and 24- or 48-hour Holter monitors. Extended cardiac event monitoring for patients with ischemic stroke or transient ischemic attack (TIA) who present with sinus rhythm can significantly increase the detection of occult AF. Such monitoring may reduce the risk of recurrent ischemic stroke by prompting the appropriate use of long-term anticoagulation. The optimal monitoring method – continuous telemetry, ambulatory electrocardiography, serial electrocardiography, transtelephonic ECG monitoring, or insertable cardiac monitors (ICMs; also sometimes referred to as implantable cardiac monitor or implantable loop recorder) – is uncertain, though longer durations of monitoring are likely to obtain the highest diagnostic yield. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Monitoring for subclinical atrial fibrillation'</a> and  <a class="medical medical_review" href="/z/d/html/1059.html" rel="external">"Stroke in patients with atrial fibrillation", section on 'Long-term anticoagulation'</a>.)</p><p>Transthoracic and transesophageal echocardiography adequately detect cardiogenic and aortic sources for cerebral embolism other than atrial fibrillation (see  <a class="medical medical_review" href="/z/d/html/5303.html" rel="external">"Echocardiography in detection of cardiac and aortic sources of systemic embolism"</a>). However, their use can be postponed to later in the hospitalization, when the patient is in a more stable clinical condition. Exceptions include patients with a moderate or high suspicion of endocarditis, where echocardiography may provide confirmation of the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Cardiac evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p class="headingAnchor" id="H100189574"><span class="h1">STROKE MANAGEMENT ISSUES</span><span class="headingEndMark"> — </span>In addition to stabilization of airway, breathing, and circulation, and rapid neurologic evaluation discussed above, early key management issues that often arise in acute stroke include blood pressure control (see <a class="local">'Blood pressure management'</a> below), fluid management (see <a class="local">'Fluids'</a> below), treatment of abnormal blood glucose levels (see <a class="local">'Hypoglycemia'</a> below and <a class="local">'Hyperglycemia'</a> below), swallowing assessment (see <a class="local">'Swallowing assessment'</a> below), and treatment of fever and infection (see <a class="local">'Fever'</a> below). Care in a dedicated stroke unit (see <a class="local">'Stroke unit care'</a> below) is associated with better outcomes.</p><p class="headingAnchor" id="H56228155"><span class="h2">Fluids</span><span class="headingEndMark"> — </span>Intravascular volume depletion is frequent in the setting of acute stroke, particularly in older adult patients [<a href="#rid12">12</a>], and may worsen cerebral blood flow. For most patients with acute stroke and volume depletion, isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> without dextrose is the agent of choice for intravascular fluid repletion and maintenance fluid therapy [<a href="#rid13">13</a>]. In general, it is best to avoid excess free water (eg, as in ½ isotonic saline) because hypotonic fluids may exacerbate cerebral edema in acute stroke and are less useful than isotonic solutions for replacing intravascular volume. In addition, it is best to avoid fluids containing glucose, which may exacerbate hyperglycemia. However, fluid management must be individualized based on cardiovascular status, electrolyte disturbances, and other conditions that may perturb fluid balance. (See  <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p>In particular, hyponatremia following subarachnoid hemorrhage may be due to inappropriate secretion of antidiuretic hormone (SIADH) or rarely, to cerebral salt wasting; these are physiologically distinct and are treated differently, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis", section on 'Hyponatremia'</a>.)</p><p class="headingAnchor" id="H100191313"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia can cause focal neurologic deficits mimicking stroke, and severe hypoglycemia alone can cause neuronal injury. It is important to check the blood sugar and rapidly correct low serum glucose (&lt;60 mg/dL [3.3 mmol/L]) at the first opportunity [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H100191613"><span class="h2">Hyperglycemia</span><span class="headingEndMark"> — </span>Hyperglycemia, generally defined as a blood glucose level &gt;126 mg/dL (&gt;7.0 mmol/L), is common in patients with acute stroke and is associated with poor functional outcome [<a href="#rid14">14-19</a>]. In a series of 59 patients with acute ischemic stroke, admission hyperglycemia was present in 32 percent of patients without diabetes and 81 percent of patients with diabetes [<a href="#rid20">20</a>]. Stress hyperglycemia may be the most common cause [<a href="#rid16">16</a>], although newly diagnosed diabetes is also important [<a href="#rid17">17</a>]. Hyperglycemia may augment brain injury by several mechanisms, including increased tissue acidosis from anaerobic metabolism, free radical generation, and increased blood brain barrier permeability [<a href="#rid21">21-23</a>]. Hyperglycemia may also rarely present as a stroke mimic [<a href="#rid24">24</a>].</p><p>In light of these observations, it is reasonable to treat severe hyperglycemia in the setting of acute stroke. The American Heart Association/American Stroke Association guidelines for acute ischemic stroke recommend treatment for hyperglycemia to achieve serum glucose concentrations in the range of 140 to 180 mg/dL (7.8 to 10 mmol/L) [<a href="#rid1">1</a>]. The European Stroke Initiative guidelines recommend treatment for glucose &gt;180 mg/dL (&gt;10 mmol/L) [<a href="#rid25">25</a>].</p><p>Tighter control of glucose with intravenous insulin does <strong>not</strong> improve functional outcome in patients with acute ischemic stroke. The multicenter SHINE trial randomly assigned over 1100 adults with hyperglycemia and acute ischemic stroke to either intensive treatment of hyperglycemia (continuous insulin infusion with a target blood glucose concentration of 80 to 130 mg/dL) or standard treatment (subcutaneous insulin on a sliding scale with a target glucose of 80 to 179 mg/dL) [<a href="#rid26">26</a>]. At 90 days, there was no difference in the proportion of patients achieving a favorable functional outcome between the intensive and standard treatment groups (20.5 versus 21.6 percent). In addition, treatment withdrawal for hypoglycemia or other adverse events was more common in the intensive treatment group (11.2 versus 3.2 percent). Similarly, a 2014 systematic review identified 11 controlled trials involving nearly over 1500 adults with acute ischemic stroke who were randomly assigned to either intensively monitored insulin infusion therapy or to usual care; there was no difference between the treatment and control groups for the combined outcome of death or dependency, and no difference between groups for the outcome of final neurologic deficit [<a href="#rid27">27</a>]. In addition, the intervention group had a higher rate of symptomatic hypoglycemia.</p><p class="headingAnchor" id="H6"><span class="h2">Swallowing assessment</span><span class="headingEndMark"> — </span>Dysphagia is common after stroke and is a major risk factor for developing aspiration pneumonia. It is important to assess swallowing function prior to administering oral medications or food. Thus, prevention of aspiration in patients with acute stroke includes initial nil per os (NPO) status until swallowing function is evaluated. (See  <a class="medical medical_review" href="/z/d/html/1093.html" rel="external">"Complications of stroke: An overview", section on 'Dysphagia'</a>.)</p><p>Note that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, if and when indicated, can be given rectally.</p><p class="headingAnchor" id="H7"><span class="h2">Head and body position</span><span class="headingEndMark"> — </span>During the acute phase of stroke, the position of the patient and the head of bed should be individualized with respect to the risk of elevated intracranial pressure and aspiration, and the presence of comorbid cardiopulmonary disease [<a href="#rid28">28</a>]. We recommend keeping the head in neutral alignment with the body and elevating the head of the bed to 30 degrees for patients in the acute phase of stroke who are at risk for any of the following problems:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated intracranial pressure (ie, intracerebral hemorrhage, cerebral edema &gt;24 hours from stroke onset in patients with large ischemic infarction)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aspiration (eg, those with dysphagia and/or diminished consciousness)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiopulmonary decompensation or oxygen desaturation (eg, those with chronic cardiac and pulmonary disease)</p><p></p><p>In the absence of these problems, we suggest keeping the head of bed in the position that is most comfortable for the patient. In addition, a cervical collar or a central intravenous line dressings, if present, should be loose enough so that they do not occlude venous outflow from the head.</p><p>A number of reports suggest that cerebral perfusion is maximal when patients are in the horizontal position [<a href="#rid29">29-31</a>]. As an example, in a study involving 20 patients with moderately severe ischemic stroke in the middle cerebral artery (MCA) territory, mean flow velocity in the MCA measured by transcranial Doppler increased by an average of 20 percent when the head-of-bed elevation decreased from 30 to 0 degrees, and by an average of 12 percent when head-of-bed elevation decreased from 30 to 15 degrees [<a href="#rid30">30</a>]. Furthermore, some patients with acute ischemic stroke may develop increased ischemic symptoms upon standing, sitting, or elevating the head of the bed, due to reduction in flow through stenotic vessels or collateral pathways [<a href="#rid32">32,33</a>]. Thus, some stroke experts have favored a supine position is preferred for nonhypoxic patients with acute ischemic stroke who are able to tolerate lying flat. When done, keeping the patient flat is a temporary measure that should be discontinued in most patients after 24 to 48 hours.</p><p>Nevertheless, the benefit of maintaining the head flat in this setting remains unproven [<a href="#rid34">34</a>]. In the HeadPoST controlled trial of over 11,000 subjects with acute stroke (85 percent ischemic) who were randomly assigned to either a lying-flat position or a sitting-up position with the head elevated to at least 30 degrees, there was no difference between treatment groups in disability outcomes, mortality, or serious adverse events [<a href="#rid35">35</a>].</p><p>Mobilization of stable patients after 24 hours may lessen the likelihood of major complications such as pneumonia, deep vein thrombosis, pulmonary embolism, and pressure sores after stroke. Exceptions may include those who exhibit neurologic deterioration upon assuming more upright postures. In addition, there is a potential increased risk of aspiration if a flat position is maintained for a prolonged period [<a href="#rid36">36</a>].</p><p>However, very early mobilization, within 24 hours of symptom onset, may be harmful [<a href="#rid37">37</a>]. The multicenter randomized AVERT trial, with over 2000 patients, evaluated a protocol of very early mobilization, which was started within 24 hours of stroke onset and consisted of frequent out-of-bed activity including sitting, standing, and walking. Compared with usual care, very early mobilization and early rehabilitative therapies reduced the odds of a favorable outcome at three months [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Fever</span><span class="headingEndMark"> — </span>The source of fever should be investigated and treated, and antipyretics should be used to lower temperature in febrile patients with acute stroke. Common etiologies of fever, including aspiration pneumonia and urinary tract infection, should also be excluded. (See  <a class="medical medical_review" href="/z/d/html/1093.html" rel="external">"Complications of stroke: An overview", section on 'Fever and infection'</a>.)</p><p>We suggest maintaining normothermia for at least the first several days after an acute stroke [<a href="#rid39">39</a>]. However, the clinical utility of this approach has not been established.</p><p class="bulletIndent1"><span class="glyph">●</span>The Paracetamol (<a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a>) In Stroke (PAIS) trial evaluated 1400 adults no later than 12 hours after symptom onset of acute ischemic stroke or intracerebral hemorrhage [<a href="#rid40">40</a>]. Included patients had a body temperature of 36 to 39ºC. Compared with placebo, paracetamol (acetaminophen) 1 g six times daily for three days did not improve outcome [<a href="#rid40">40</a>]. However, a post-hoc subgroup analysis of 661 patients with a baseline body temperature of 37 to 39ºC suggested benefit for paracetamol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and meta-analysis of five small randomized controlled trials with a total of 293 patients, there was no benefit for pharmacologic temperature reduction for acute stroke [<a href="#rid41">41</a>]. All the trials enrolled patients within 24 hours of stroke onset, and the duration of treatment ranged from 24 hours to five days. With addition of results from the PAIS trial, the updated meta-analysis found no difference between active treatment and control for a favorable outcome (odds ratio [OR] 1.1, 95% CI 0.9-1.3) [<a href="#rid40">40</a>].</p><p></p><p>Larger trials are needed to determine if pharmacologic temperature reduction improves outcome from acute stroke, particularly for patients with temperature of ≥37ºC, though it seems unlikely that <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> will be effective by itself. In patients who are nil per os (NPO), acetaminophen is now available in the United States as an intravenous preparation.</p><p>Induced hypothermia is not currently recommended for patients with ischemic stroke, outside of clinical trials [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H68922375"><span class="h2">Stroke unit care</span><span class="headingEndMark"> — </span>Evidence suggests that patients with acute stroke have better outcomes when admitted to a hospital unit that is specialized for the care of patients with all types of acute stroke, including ischemic, intracerebral hemorrhage, and subarachnoid hemorrhage [<a href="#rid42">42-46</a>]. The precise components of an acute stroke unit vary between centers and countries, but generally include a hospital ward with dedicated telemetry beds that is continuously staffed by a team of physicians, nurses and other personnel who specialize in stroke care, emphasizing expertise in vascular neurology and neurosurgery [<a href="#rid47">47,48</a>]. Additional components include prompt availability of neuroimaging (eg, CT, MRI, various types of angiography, ultrasound, transcranial Doppler) and cardiac imaging. Implementation of stroke protocols and disease-performance measures may contribute to improved outcomes and decreased risk of stroke-related complications, as shown in some reports [<a href="#rid49">49,50</a>].</p><p>Current national guidelines support stroke unit care, when available, for patients with suspected acute stroke [<a href="#rid1">1,51</a>].</p><p class="headingAnchor" id="H14"><span class="h1">BLOOD PRESSURE MANAGEMENT</span><span class="headingEndMark"> — </span>The approach to blood pressure management in acute ischemic stroke is inherently different from the approach in acute hemorrhagic stroke. For this reason, a neuroimaging study with CT or MRI is critical to help guide blood pressure therapy in patients with acute stroke. Likewise, there are important differences between the blood pressure management in the acute and chronic phases of stroke.</p><p>The management of blood pressure in acute phase of stroke is reviewed in the sections that follow. The management of blood pressure after the acute phase of stroke is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3823.html" rel="external">"Antihypertensive therapy for secondary stroke prevention"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Blood pressure in acute ischemic stroke</span><span class="headingEndMark"> — </span>The long-term benefit from antihypertensive therapy does not mean that a reduction in blood pressure will be beneficial during initial management of an acute ischemic stroke [<a href="#rid52">52</a>]. In patients with ischemic stroke, the perfusion pressure distal to the obstructed vessel is low, and the distal vessels are dilated. Because of impaired cerebral autoregulation  (<a class="graphic graphic_figure graphicRef57676" href="/z/d/graphic/57676.html" rel="external">figure 2</a>), blood flow in these dilated vessels is thought to be dependent upon the systemic blood pressure.</p><p>The arterial blood pressure is usually elevated in patients with an acute stroke. This may be due to chronic hypertension, an acute sympathetic response, or other stroke-mediated mechanisms [<a href="#rid53">53</a>]. In many cases, however, the acutely elevated blood pressure is necessary to maintain brain perfusion in borderline ischemic areas [<a href="#rid54">54</a>].</p><p>The observation that the blood pressure frequently rises spontaneously following cerebral ischemia is consistent with this protective hypothesis, although a stress response to the acute event and to hospitalization may also contribute [<a href="#rid55">55</a>]. The hypertensive effect is transient, as blood pressure falls by as much as 20/10 mmHg within 10 days.</p><p>An analysis from the International Stroke Trial of 17,398 patients with an ischemic stroke noted a U-shaped relationship between baseline systolic blood pressure and outcomes [<a href="#rid56">56</a>]. Elevated systolic blood pressure was associated with an increased risk of recurrent ischemic stroke (50 percent greater risk of recurrence with a systolic blood pressure of &gt;200 mmHg versus 130 mmHg), while low blood pressure (particularly &lt;120 mmHg) was associated with an excess number of deaths from coronary heart disease.</p><p>A subsequent analysis of 1004 patients with acute ischemic stroke from Okinawa also found a U-shaped relationship between admission blood pressure and death within 30 days after stroke onset [<a href="#rid57">57</a>]. The U-shaped relationship was shifted toward higher pressure in patients who had previous hypertension compared with those who did not have previous hypertension. This finding mirrors the shift seen in cerebral autoregulation that occurs in longstanding hypertension  (<a class="graphic graphic_figure graphicRef57676" href="/z/d/graphic/57676.html" rel="external">figure 2</a>) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Effect of lowering blood pressure</span><span class="headingEndMark"> — </span>There are few data from randomized controlled trials specifically designed to guide blood pressure management in the acute phase of ischemic stroke (ie, the first 24 hours) when the ischemic penumbra may be at risk of irreversible damage if cerebral blood flow is reduced by lowering the blood pressure [<a href="#rid59">59</a>]. The MAPAS trial found no clear benefit for blood pressure lowering within 12 hours of acute ischemic stroke onset, but an adjusted analysis suggested that a goal systolic blood pressure of 161 to 180 mmHg increased the odds of a good outcome compared with higher or lower goal blood pressures [<a href="#rid60">60</a>]. The RIGHT-2 trial found that lowering blood pressure within four hours of onset of suspected stroke did not improve functional outcomes; the results are confounded by inclusion of patients with transient ischemic attack (TIA), intracerebral hemorrhage, and stroke mimics [<a href="#rid61">61</a>]. Lowering the systemic blood pressure in patients within 24 hours of acute ischemic stroke onset has been associated with clinical deterioration in several observational studies [<a href="#rid62">62-64</a>].</p><p>Other large trials (eg, CATIS [<a href="#rid65">65</a>], SCAST [<a href="#rid66">66</a>], COSSACS [<a href="#rid67">67</a>], and ENOS [<a href="#rid68">68</a>]) enrolled patients as long as 30 to 48 hours after stroke onset, and are therefore less informative regarding the impact of blood pressure treatment in the first hours of ischemic stroke. In addition, many of these trials, including the meta-analyses discussed below, enrolled patients with intracerebral hemorrhage, a group that might be expected to benefit from early blood pressure lowering. Keeping these limitations in mind, some of the randomized trial data suggest that initiating blood pressure reduction in acute stroke or merely continuing prestroke blood pressure medications can be harmful:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2014 meta-analysis of 16 trials (including ENOS) of antihypertensive medications that included over 19,000 patients with acute stroke, early blood pressure reduction had no effect on functional outcome (OR 1.0, 95% CI 0.93-1.07) [<a href="#rid68">68</a>]. Similarly, a 2015 meta-analysis of 13 randomized trials (also including ENOS) and over 12,000 subjects found that blood pressure lowering started within three days of ischemic stroke onset did not alter the risk of death or dependency at three months or trial end point (relative risk, 1.04, 95% CI 0.96-1.13) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of individual patient data from COSSACS and ENOS trials found that continuing versus stopping antihypertensive treatment had no effect on the risk of death or dependency at final follow-up [<a href="#rid70">70</a>]. However, in a subgroup analysis, patients who stopped antihypertensives within 12 hours of stroke onset showed a nonsignificant trend towards less death or dependency. In the ENOS trial itself, the group assigned to continuing blood pressure treatment had an increased likelihood of hospital death or discharge to an institution, an increased risk of death or disability (Barthel index &lt;60) at 90 days, and significantly lower cognition scores at 90 days compared with the group that stopped treatment, even though there was no difference in functional outcome between the two groups [<a href="#rid68">68</a>].</p><p></p><p>These results are not definitive for the reasons noted above.</p><p class="headingAnchor" id="H17"><span class="h3">Blood pressure goals in ischemic stroke</span><span class="headingEndMark"> — </span>Special considerations apply to blood pressure control in patients with acute ischemic stroke who are eligible for intravenous thrombolytic therapy. Before thrombolytic therapy is started, treatment is recommended so that systolic blood pressure is ≤185 mmHg and diastolic blood pressure is ≤110 mmHg  (<a class="graphic graphic_table graphicRef50725" href="/z/d/graphic/50725.html" rel="external">table 6</a>) [<a href="#rid1">1</a>]. The blood pressure should be stabilized and maintained at or below 180/105 mmHg for at least 24 hours after thrombolytic treatment. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16134.html" rel="external">"Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use", section on 'Management of blood pressure'</a>.)</p><p>For patients with ischemic stroke who are not treated with thrombolytic therapy, blood pressure should <strong>not</strong> be treated acutely unless the hypertension is extreme (systolic blood pressure &gt;220 mmHg or diastolic blood pressure &gt;120 mmHg), or the patient has active ischemic coronary disease, heart failure, aortic dissection, hypertensive encephalopathy, or pre-eclampsia/eclampsia [<a href="#rid1">1,71</a>]. When treatment is indicated, cautious lowering of blood pressure by approximately 15 percent during the first 24 hours after stroke onset is suggested.</p><p>It is reasonable to start or restart antihypertensive medications during hospitalization for patients with blood pressure &gt;140/90 mmHg who are neurologically stable, unless contraindicated [<a href="#rid1">1</a>]. This can be done as early as 24 to 48 hours after stroke onset for most hospitalized patients, with the goal of gradually controlling hypertension within a few days to a week [<a href="#rid72">72</a>]. Importantly, patients with extracranial or intracranial large artery stenoses may require a slower reduction in blood pressure (eg, over 7 to 14 days after ischemic stroke), as some degree of blood pressure elevation may be necessary to maintain cerebral blood flow to ischemic brain regions. For this reason, we suggest not restarting antihypertensive agents until after vascular imaging is completed and a symptomatic large artery stenosis is excluded.</p><p>If acute antihypertensive therapy is needed, intravenous agents are generally used. (See <a class="local">'Choice of antihypertensive agent'</a> below.)</p><p>Systemic hypotension and hypovolemia should be corrected to improve cerebral blood flow and systemic organ function [<a href="#rid1">1</a>]. However, drug-induced hypertension is unproven for the treatment of ischemic stroke.</p><p class="headingAnchor" id="H1801652926"><span class="h3">Choice of antihypertensive agent</span><span class="headingEndMark"> — </span>In the acute phase of stroke, there is no good evidence to support the use of any specific antihypertensive agent to achieve recommended blood pressure goals. Nevertheless, reversible and titratable intravenous agents are best suited for precise blood pressure lowering. Consensus guidelines suggest intravenous <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>, <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, and <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">clevidipine</a> as first-line antihypertensive agents if pharmacologic therapy is necessary in the acute phase, since they allow rapid and safe titration to the goal blood pressure  (<a class="graphic graphic_table graphicRef50725" href="/z/d/graphic/50725.html" rel="external">table 6</a>) [<a href="#rid1">1</a>].</p><p>Intravenous <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> should be considered second-line therapy since it carries added theoretical risks of increasing intracranial pressure or affecting platelet function. Medications likely to cause a prolonged or precipitous decline in blood pressure (eg, rapid-acting formulations of <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>) should be avoided. In addition, their use is associated with an increased risk of stroke, particularly in older adult patients [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Blood pressure in acute hemorrhagic stroke</span><span class="headingEndMark"> — </span>In both intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), the approach to blood pressure management must take into account the potential benefits (eg, reducing further bleeding) and risks (eg, reducing cerebral perfusion) of blood pressure lowering. Recommendations for blood pressure management in acute ICH and SAH are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis", section on 'Blood pressure management'</a> and  <a class="medical medical_review" href="/z/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis", section on 'Blood pressure control'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">ACUTE THERAPY</span></p><p class="headingAnchor" id="H2191640006"><span class="h2">Ischemic stroke management</span><span class="headingEndMark"> — </span>For eligible patients  (<a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">table 2</a>) with acute ischemic stroke, intravenous thrombolysis is first-line therapy, provided that treatment is initiated within the appropriate time window  (<a class="graphic graphic_algorithm graphicRef141876" href="/z/d/graphic/141876.html" rel="external">algorithm 1</a>). Because the benefit of intravenous thrombolysis is time dependent, it is critical to treat patients as quickly as possible.</p><p>Mechanical thrombectomy  (<a class="graphic graphic_algorithm graphicRef141874" href="/z/d/graphic/141874.html" rel="external">algorithm 2</a>) is indicated for patients with acute ischemic stroke due to a large artery occlusion in the anterior circulation who can be treated within 24 hours of symptom onset or the time last known to be well at stroke centers with appropriate expertise, regardless of whether they receive intravenous thrombolytic therapy for the same ischemic stroke event. The eligibility criteria and utility of thrombolytic therapy, endovascular thrombectomy, and the treatment of patients not eligible for thrombolysis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">"Mechanical thrombectomy for acute ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p>In addition to intravenous thrombolysis and endovascular thrombectomy, a number of interventions for ischemic stroke are associated with either reduced disability, complications, or stroke recurrence, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Antithrombotic therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> initiated as soon as possible after stroke onset (see  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Efficacy of aspirin'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylaxis for deep venous thrombosis and pulmonary embolism (see  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke", section on 'Approach to VTE prevention'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antithrombotic therapy at discharge (see  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipid lowering with high intensity statin therapy (see  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke", section on 'LDL-C lowering therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure reduction after the acute phase of ischemic stroke has passed (see  <a class="medical medical_review" href="/z/d/html/3823.html" rel="external">"Antihypertensive therapy for secondary stroke prevention"</a> and  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a>); management of blood pressure in the acute phase of ischemic stroke is discussed above (see <a class="local">'Blood pressure management'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behavioral and lifestyle changes including smoking cessation, exercise, weight reduction for patients with obesity, and a Mediterranean style diet (see  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>)</p><p></p><p>Appropriate and timely use of these therapies should be considered as soon as ischemic stroke is recognized. Utilization of these interventions may be improved by the use of standardized stroke care orders or critical pathways beginning with hospital admission through discharge [<a href="#rid1">1,74</a>].</p><p>Full-dose anticoagulation is rarely indicated in the hyperacute phase of ischemic stroke, although low-dose heparin anticoagulation is often used for prevention of venous thromboembolism in patients with restricted mobility. (See  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke"</a>.)</p><p>The main indication for oral anticoagulation after ischemic stroke is atrial fibrillation. When indicated, oral anticoagulation can be started immediately for patients with a transient ischemic attack, and soon after ischemic stroke onset for medically stable patients with a small- or moderate-sized infarct and no bleeding complications or uncontrolled hypertension. For patients with atrial fibrillation who have a large infarct, symptomatic hemorrhagic transformation, or poorly controlled hypertension, withholding oral anticoagulation for one to two weeks is generally recommended. (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Cardioembolic source'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statin therapy</strong> – For patients with acute ischemic stroke, we suggest starting or continuing statin treatment as soon as oral medications can be used safely. There is clear evidence that long-term intensive statin therapy is associated with a reduced risk of recurrent ischemic stroke and cardiovascular events, as discussed separately (see  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke", section on 'LDL-C lowering therapy'</a>). The utility of statin therapy during the acute phase of ischemic stroke is less well studied, but is supported by the following observations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A single-center randomized controlled trial of 89 patients who were already treated with a statin and were assigned to continuation or cessation of statin therapy in the acute phase of ischemic stroke [<a href="#rid75">75</a>]. The rate of death or dependency at three months was significantly lower with continuation of statin treatment (39 versus 60 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An observational study, which evaluated over 12,000 subjects hospitalized with ischemic stroke, found that statin use before and during hospitalization was associated with improved outcome at hospital discharge and with improved survival at one year [<a href="#rid76">76,77</a>]. Furthermore, initiation of statin treatment early in hospitalization was associated with improved survival, while statin discontinuation early in hospitalization, even for a short period, was associated with decreased survival.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An uncontrolled study of 448 patients reported that new or continued statin treatment in the first 72 hours after acute ischemic stroke was associated with improved early and late (one-year) survival [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An observational study of 2072 patients who received intravenous thrombolysis for acute ischemic stroke found that statin treatment started within 72 hours of thrombolysis was associated with a favorable functional outcome and a reduced risk of death at three months [<a href="#rid79">79</a>]. Of the 839 patients treated with statins, 65 percent were statin naïve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSRIs</strong> – For patients with hemiparesis but without depression after ischemic stroke, evidence from a few small randomized controlled trials (including the FLAME trial) suggested that early initiation of selective serotonin-reuptake inhibitors (SSRIs) enhanced motor recovery and reduced dependency [<a href="#rid80">80-82</a>]. However, subsequent randomized controlled trials, including the FOCUS, AFFINITY, and EFFECTS trials, which together enrolled over 5900 adult patients with acute ischemic stroke or intracerebral hemorrhage, found no benefit in functional outcome at six months for treatment with <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> compared with placebo [<a href="#rid83">83-85</a>]. Treatment with fluoxetine reduced the risk of developing depression in FOCUS and EFFECTS but increased the risk of bone fractures in all three trials, increased the risks of falls and epileptic seizures in AFFINITY, and increased the risk of hyponatremia in EFFECTS.</p><p></p><p class="headingAnchor" id="H10064162"><span class="h2">Intracranial hemorrhage management</span><span class="headingEndMark"> — </span>The treatment of patients with intracerebral hemorrhage or subarachnoid hemorrhage is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/16134.html" rel="external">"Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use", section on 'Management of symptomatic intracerebral hemorrhage'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Neuroprotective treatment</span><span class="headingEndMark"> — </span>Numerous neuroprotective agents have shown promising results in animal experiments. However, clinical trials have thus far failed to confirm consistent benefit [<a href="#rid86">86</a>]. This failure may be due, at least in part, to limitations of animal models of acute stroke and to shortcomings of clinical trials.</p><p>The search for effective neuroprotective treatment continues [<a href="#rid86">86-91</a>]. As examples, nerinetide and remote ischemic conditioning have shown signals suggesting benefit in some clinical trials [<a href="#rid91">91-95</a>]. More study is needed to determine if these treatments are safe and effective for acute ischemic stroke.</p><p class="headingAnchor" id="H25"><span class="h1">PREVENTION OF COMPLICATIONS</span><span class="headingEndMark"> — </span>The prevention of medical complications of stroke is an important goal of stroke management, and this aspect of care begins with initial evaluation of the patient. Common acute and subacute medical problems associated with stroke include:</p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial infarction</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia</p><p class="bulletIndent1"><span class="glyph">●</span>Aspiration pneumonia</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract infection</p><p class="bulletIndent1"><span class="glyph">●</span>Deep vein thrombosis</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary embolism</p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration</p><p class="bulletIndent1"><span class="glyph">●</span>Malnutrition</p><p class="bulletIndent1"><span class="glyph">●</span>Pressure sores</p><p class="bulletIndent1"><span class="glyph">●</span>Orthopedic complications and contractures</p><p></p><p>The prevention, impact, and management of these complications are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1093.html" rel="external">"Complications of stroke: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke"</a>.)</p><p>Delirium, characterized by a disturbance of consciousness with decreased attention and disorganized thinking, is another potential complication of stroke [<a href="#rid96">96</a>]. Findings from systematic reviews and meta-analyses suggest that the rate of post-stroke delirium is approximately 25 percent [<a href="#rid97">97,98</a>]. Patients with delirium have longer hospital stays and higher inpatient and 12-month mortality rates [<a href="#rid97">97</a>]. Risk factors for developing post-stroke delirium include preexisting cognitive decline, infection, and greater stroke severity [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a> and  <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">"Delirium and acute confusional states: Prevention, treatment, and prognosis"</a>.)</p><p class="headingAnchor" id="H3015791931"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">"Society guideline links: Stroke in adults"</a>.)</p><p class="headingAnchor" id="H28957248"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15328.html" rel="external">"Patient education: Stroke (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16221.html" rel="external">"Patient education: Intracerebral hemorrhage (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/726.html" rel="external">"Patient education: Stroke symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/723.html" rel="external">"Patient education: Ischemic stroke treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H94773002"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Main goals of initial evaluation</strong> – The main goals in the initial phase of acute stroke management are to ensure medical stability, to quickly reverse conditions that are contributing to the patient's problem, to determine if patients with acute ischemic stroke are candidates for reperfusion therapy, and to begin to uncover the pathophysiologic basis of the neurologic symptoms. (See <a class="local">'Initial assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important aspects of immediate assessment</strong> – Important aspects of acute stroke evaluation and management include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vital signs</strong> – Assess vital signs and stabilize airway, breathing, and circulation. (See <a class="local">'Airway, breathing, and circulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rapid history and examination</strong> – Obtain a rapid but accurate history and examination to help distinguish stroke mimics and other disorders in the differential diagnosis  (<a class="graphic graphic_table graphicRef69869" href="/z/d/graphic/69869.html" rel="external">table 1</a>) of acute stroke. (See <a class="local">'History and physical'</a> above and <a class="local">'Neurologic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urgent brain imaging</strong> – Obtain urgent brain imaging (with CT or MRI), neurovascular imaging (with CT angiography or magnetic resonance angiography [MRA]) and other important laboratory studies, including cardiac monitoring during the first 24 hours after the onset of ischemic stroke. (See <a class="local">'Immediate laboratory studies'</a> above and <a class="local">'Neuroimaging'</a> above and <a class="local">'Cardiac studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluid management</strong> – Manage volume depletion and electrolyte disturbances. (See <a class="local">'Fluids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Check serum glucose</strong> – Low serum glucose (&lt;60 mg/dL [3.3 mmol/L]) should be corrected rapidly. It is reasonable to treat hyperglycemia if the glucose level is &gt;180 mg/dL (&gt;10 mmol/L) with a goal of keeping serum glucose levels within a range of 140 to 180 mg/dL (7.8 to 10 mmol/L).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Check swallowing</strong> – All patients with acute stroke should be assessed for ability to swallow in order to prevent aspiration. (See <a class="local">'Swallowing assessment'</a> above and  <a class="medical medical_review" href="/z/d/html/1093.html" rel="external">"Complications of stroke: An overview", section on 'Dysphagia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Optimize head of bed position</strong> – For patients with intracerebral hemorrhage, subarachnoid hemorrhage, or ischemic stroke who are at risk for elevated intracranial pressure, aspiration, cardiopulmonary decompensation, or oxygen desaturation, we recommend keeping the head in neutral alignment with the body and elevating the head of the bed to 30 degrees (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). For patients with stroke who are not at high risk for these complications, we suggest keeping the head of the bed in the position that is most comfortable. (See <a class="local">'Head and body position'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Check for fever</strong> – Evaluate and treat the source of fever, if present; for patients with acute stroke, we suggest maintaining normothermia for at least the first several days after an acute stroke (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Fever'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure management</strong> – The management of blood pressure in acute stroke depends on the type of stroke and anticipated treatment. (See <a class="local">'Blood pressure management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombolytic therapy</strong> – For patients with acute ischemic stroke who will receive intravenous thrombolytic therapy, antihypertensive treatment is recommended so that systolic blood pressure is ≤185 mmHg and diastolic blood pressure is ≤110 mmHg prior to treatment and &lt;180/105 mmHg for the first 24 hours after treatment  (<a class="graphic graphic_table graphicRef50725" href="/z/d/graphic/50725.html" rel="external">table 6</a>). This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16134.html" rel="external">"Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use", section on 'Management of blood pressure'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No thrombolytic therapy</strong> – For patients with acute ischemic stroke who are <strong>not</strong> treated with thrombolytic therapy, we suggest treating high blood pressure only if the hypertension is extreme (systolic blood pressure &gt;220 mmHg or diastolic blood pressure &gt;120 mmHg), or if the patient has another clear indication (active ischemic coronary disease, heart failure, aortic dissection, hypertensive encephalopathy, or pre-eclampsia/eclampsia) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). When treatment is indicated, we suggest cautious lowering of blood pressure by approximately 15 percent during the first 24 hours after stroke onset (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Blood pressure goals in ischemic stroke'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemorrhagic stroke</strong> – In both intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), the approach to blood pressure lowering must account for the potential benefits (eg, reducing further bleeding) and risks (eg, reducing cerebral perfusion). Recommendations for blood pressure management in acute ICH and SAH are discussed in detail separately. (See <a class="local">'Blood pressure in acute hemorrhagic stroke'</a> above and  <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis", section on 'Blood pressure management'</a> and  <a class="medical medical_review" href="/z/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis", section on 'Blood pressure control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eligibility for reperfusion therapy</strong> – For eligible patients  (<a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">table 2</a>) with acute ischemic stroke, intravenous thrombolytic therapy is first-line therapy, provided that treatment is initiated within the appropriate time window  (<a class="graphic graphic_algorithm graphicRef141876" href="/z/d/graphic/141876.html" rel="external">algorithm 1</a>). Patients with acute ischemic stroke due to a proximal large artery occlusion who can be treated within 24 hours of time last known to be at neurologic baseline should be evaluated for treatment with mechanical thrombectomy  (<a class="graphic graphic_algorithm graphicRef141874" href="/z/d/graphic/141874.html" rel="external">algorithm 2</a>). The eligibility criteria and utility of thrombolytic therapy, mechanical thrombectomy, and the treatment of patients not eligible for thrombolysis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">"Mechanical thrombectomy for acute ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other early interventions that improve outcome</strong> – In addition to reperfusion therapy, a number of interventions for ischemic stroke are associated with either reduced disability, complications, or stroke recurrence, including (see <a class="local">'Acute therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiplatelet therapy</strong> – Antiplatelet agents should be started as soon as possible after the diagnosis of ischemic stroke is confirmed, even before the evaluation for ischemic mechanism is complete. (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Treatment on presentation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylaxis for venous thromboembolism</strong> – Prophylaxis for deep venous thrombosis and pulmonary embolism is indicated for all patients with acute stroke and restricted mobility. (See  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke", section on 'Approach to VTE prevention'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Statin therapy</strong> – For patients with acute ischemic stroke, we suggest starting or continuing statin treatment as soon as oral medications can be used safely (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Ischemic stroke management'</a> above.)</p><p></p><p class="headingAnchor" id="H522152000"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Walter J Koroshetz, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019; 50:e344.</a></li><li><a class="nounderline abstract_t">Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016; 47:581.</a></li><li><a class="nounderline abstract_t">Hsieh CY, Chen CH, Sung SF, Hwang WJ. Parkinsonism or Other Movement Disorders Presenting as Stroke Mimics. Acta Neurol Taiwan 2016; 25(4):124.</a></li><li><a class="nounderline abstract_t">Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46:2032.</a></li><li><a class="nounderline abstract_t">Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012; 43:1711.</a></li><li><a class="nounderline abstract_t">Kothari R, Hall K, Brott T, Broderick J. Early stroke recognition: developing an out-of-hospital NIH Stroke Scale. Acad Emerg Med 1997; 4:986.</a></li><li><a class="nounderline abstract_t">Goldstein LB, Simel DL. Is this patient having a stroke? JAMA 2005; 293:2391.</a></li><li><a class="nounderline abstract_t">Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28:2119.</a></li><li><a class="nounderline abstract_t">Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53:126.</a></li><li><a class="nounderline abstract_t">Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655.</a></li><li><a class="nounderline abstract_t">Michaels AD, Spinler SA, Leeper B, et al. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation 2010; 121:1664.</a></li><li><a class="nounderline abstract_t">Rodriguez GJ, Cordina SM, Vazquez G, et al. The hydration influence on the risk of stroke (THIRST) study. Neurocrit Care 2009; 10:187.</a></li><li><a class="nounderline abstract_t">Burns JD, Green DM, Metivier K, DeFusco C. Intensive care management of acute ischemic stroke. Emerg Med Clin North Am 2012; 30:713.</a></li><li><a class="nounderline abstract_t">Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997; 314:1303.</a></li><li><a class="nounderline abstract_t">Bruno A, Biller J, Adams HP Jr, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999; 52:280.</a></li><li><a class="nounderline abstract_t">Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32:2426.</a></li><li><a class="nounderline abstract_t">Dave JA, Engel ME, Freercks R, et al. Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review. QJM 2010; 103:495.</a></li><li><a class="nounderline abstract_t">Béjot Y, Aboa-Eboulé C, Hervieu M, et al. The deleterious effect of admission hyperglycemia on survival and functional outcome in patients with intracerebral hemorrhage. Stroke 2012; 43:243.</a></li><li><a class="nounderline abstract_t">Zonneveld TP, Nederkoorn PJ, Westendorp WF, et al. Hyperglycemia predicts poststroke infections in acute ischemic stroke. Neurology 2017; 88:1415.</a></li><li><a class="nounderline abstract_t">Allport L, Baird T, Butcher K, et al. Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. Diabetes Care 2006; 29:1839.</a></li><li><a class="nounderline abstract_t">Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke 2004; 35:363.</a></li><li><a class="nounderline abstract_t">Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 2002; 52:20.</a></li><li><a class="nounderline abstract_t">Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002; 59:669.</a></li><li><a class="nounderline abstract_t">Shah NH, Velez V, Casanova T, Koch S. Hyperglycemia presenting as left middle cerebral artery stroke: a case report. J Vasc Interv Neurol 2014; 7:9.</a></li><li><a class="nounderline abstract_t">European Stroke Initiative Executive Committee, EUSI Writing Committee, Olsen TS, et al. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis 2003; 16:311.</a></li><li><a class="nounderline abstract_t">Johnston KC, Bruno A, Pauls Q, et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA 2019; 322:326.</a></li><li><a class="nounderline abstract_t">Bellolio MF, Gilmore RM, Ganti L. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev 2014; :CD005346.</a></li><li><a class="nounderline abstract_t">Summers D, Leonard A, Wentworth D, et al. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association. Stroke 2009; 40:2911.</a></li><li><a class="nounderline abstract_t">Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke 2002; 33:497.</a></li><li><a class="nounderline abstract_t">Wojner-Alexander AW, Garami Z, Chernyshev OY, Alexandrov AV. Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology 2005; 64:1354.</a></li><li><a class="nounderline abstract_t">Favilla CG, Mesquita RC, Mullen M, et al. Optical bedside monitoring of cerebral blood flow in acute ischemic stroke patients during head-of-bed manipulation. Stroke 2014; 45:1269.</a></li><li><a class="nounderline abstract_t">Toole JF. Effects of change of head, limb and body position on cephalic circulation. N Engl J Med 1968; 279:307.</a></li><li><a class="nounderline abstract_t">Caplan LR, Sergay S. Positional cerebral ischaemia. J Neurol Neurosurg Psychiatry 1976; 39:385.</a></li><li><a class="nounderline abstract_t">Anderson CS, Olavarría VV. Head Positioning in Acute Stroke: Down but Not Out. Stroke 2019; 50:224.</a></li><li><a class="nounderline abstract_t">Anderson CS, Arima H, Lavados P, et al. Cluster-Randomized, Crossover Trial of Head Positioning in Acute Stroke. N Engl J Med 2017; 376:2437.</a></li><li><a class="nounderline abstract_t">Fernández-Crehuet R, Díaz-Molina C, de Irala J, et al. Nosocomial infection in an intensive-care unit: identification of risk factors. Infect Control Hosp Epidemiol 1997; 18:825.</a></li><li><a class="nounderline abstract_t">Langhorne P, Collier JM, Bate PJ, et al. Very early versus delayed mobilisation after stroke. Cochrane Database Syst Rev 2018; 10:CD006187.</a></li><li><a class="nounderline abstract_t">AVERT Trial Collaboration group, Bernhardt J, Langhorne P, et al. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet 2015; 386:46.</a></li><li><a class="nounderline abstract_t">Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke 1998; 29:529.</a></li><li><a class="nounderline abstract_t">den Hertog HM, van der Worp HB, van Gemert HM, et al. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 2009; 8:434.</a></li><li><a class="nounderline abstract_t">Den Hertog HM, van der Worp HB, Tseng MC, Dippel DW. Cooling therapy for acute stroke. Cochrane Database Syst Rev 2009; :CD001247.</a></li><li><a class="nounderline abstract_t">Candelise L, Gattinoni M, Bersano A, et al. Stroke-unit care for acute stroke patients: an observational follow-up study. Lancet 2007; 369:299.</a></li><li><a class="nounderline abstract_t">Meretoja A, Roine RO, Kaste M, et al. Effectiveness of primary and comprehensive stroke centers: PERFECT stroke: a nationwide observational study from Finland. Stroke 2010; 41:1102.</a></li><li><a class="nounderline abstract_t">Di Carlo A, Lamassa M, Wellwood I, et al. Stroke unit care in clinical practice: an observational study in the Florence center of the European Registers of Stroke (EROS) Project. Eur J Neurol 2011; 18:686.</a></li><li><a class="nounderline abstract_t">Langhorne P, O'Donnell MJ, Chin SL, et al. Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet 2018; 391:2019.</a></li><li><a class="nounderline abstract_t">Langhorne P, Ramachandra S, Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke: network meta-analysis. Cochrane Database Syst Rev 2020; 4:CD000197.</a></li><li><a class="nounderline abstract_t">Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition. Stroke 2011; 42:2651.</a></li><li><a class="nounderline abstract_t">Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 2005; 36:1597.</a></li><li><a class="nounderline abstract_t">Alberts MJ. Stroke centers: proof of concept and the concept of proof. Stroke 2010; 41:1100.</a></li><li><a class="nounderline abstract_t">Middleton S, McElduff P, Ward J, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet 2011; 378:1699.</a></li><li><a class="nounderline abstract_t">European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457.</a></li><li><a class="nounderline abstract_t">Berge E. Should high blood pressure be lowered in the acute stroke? J Hypertens 2011; 29:1478.</a></li><li><a class="nounderline abstract_t">Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation 2008; 118:176.</a></li><li><a class="nounderline abstract_t">Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke 2009; 40:2251.</a></li><li><a class="nounderline abstract_t">Wallace JD, Levy LL. Blood pressure after stroke. JAMA 1981; 246:2177.</a></li><li><a class="nounderline abstract_t">Leonardi-Bee J, Bath PM, Phillips SJ, et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315.</a></li><li><a class="nounderline abstract_t">Okumura K, Ohya Y, Maehara A, et al. Effects of blood pressure levels on case fatality after acute stroke. J Hypertens 2005; 23:1217.</a></li><li><a class="nounderline abstract_t">Bath PM. How to manage blood pressure in acute stroke. J Hypertens 2005; 23:1135.</a></li><li><a class="nounderline abstract_t">Saver JL. Time is brain--quantified. Stroke 2006; 37:263.</a></li><li><a class="nounderline abstract_t">Nasi LA, Martins SCO, Gus M, et al. Early Manipulation of Arterial Blood Pressure in Acute Ischemic Stroke (MAPAS): Results of a Randomized Controlled Trial. Neurocrit Care 2019; 30:372.</a></li><li><a class="nounderline abstract_t">RIGHT-2 Investigators. Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. Lancet 2019; 393:1009.</a></li><li><a class="nounderline abstract_t">Oliveira-Filho J, Silva SC, Trabuco CC, et al. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology 2003; 61:1047.</a></li><li><a class="nounderline abstract_t">Vlcek M, Schillinger M, Lang W, et al. Association between course of blood pressure within the first 24 hours and functional recovery after acute ischemic stroke. Ann Emerg Med 2003; 42:619.</a></li><li><a class="nounderline abstract_t">Castillo J, Leira R, García MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004; 35:520.</a></li><li><a class="nounderline abstract_t">He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA 2014; 311:479.</a></li><li><a class="nounderline abstract_t">Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741.</a></li><li><a class="nounderline abstract_t">Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010; 9:767.</a></li><li><a class="nounderline abstract_t">ENOS Trial Investigators, Bath PM, Woodhouse L, et al. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385:617.</a></li><li><a class="nounderline abstract_t">Lee M, Ovbiagele B, Hong KS, et al. Effect of Blood Pressure Lowering in Early Ischemic Stroke: Meta-Analysis. Stroke 2015; 46:1883.</a></li><li><a class="nounderline abstract_t">Woodhouse LJ, Manning L, Potter JF, et al. Continuing or Temporarily Stopping Prestroke Antihypertensive Medication in Acute Stroke: An Individual Patient Data Meta-Analysis. Hypertension 2017; 69:933.</a></li><li class="breakAll">National Institute for Health and Clinical Excellence. Stroke: The diagnosis and acute management of stroke and transient ischaemic attacks. Royal College of Physicians, London 2008. http://www.nice.org.uk/CG068 (Accessed on February 01, 2011).</li><li><a class="nounderline abstract_t">Rodríguez-García JL, Botia E, de La Sierra A, et al. Significance of elevated blood pressure and its management on the short-term outcome of patients with acute ischemic stroke. Am J Hypertens 2005; 18:379.</a></li><li><a class="nounderline abstract_t">Jung SY, Choi NK, Kim JY, et al. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology 2011; 77:1229.</a></li><li><a class="nounderline abstract_t">California Acute Stroke Pilot Registry Investigators. The impact of standardized stroke orders on adherence to best practices. Neurology 2005; 65:360.</a></li><li><a class="nounderline abstract_t">Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69:904.</a></li><li><a class="nounderline abstract_t">Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012; 43:147.</a></li><li><a class="nounderline abstract_t">Flint AC, Kamel H, Navi BB, et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology 2012; 78:1678.</a></li><li><a class="nounderline abstract_t">Ní Chróinín D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke 2011; 42:1021.</a></li><li><a class="nounderline abstract_t">Cappellari M, Bovi P, Moretto G, et al. The THRombolysis and STatins (THRaST) study. Neurology 2013; 80:655.</a></li><li><a class="nounderline abstract_t">Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012; 11:CD009286.</a></li><li><a class="nounderline abstract_t">Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10:123.</a></li><li><a class="nounderline abstract_t">Mead GE, Hsieh CF, Hackett M. Selective serotonin reuptake inhibitors for stroke recovery. JAMA 2013; 310:1066.</a></li><li><a class="nounderline abstract_t">FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2019; 393:265.</a></li><li><a class="nounderline abstract_t">AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19:651.</a></li><li><a class="nounderline abstract_t">EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19:661.</a></li><li><a class="nounderline abstract_t">Chamorro Á, Lo EH, Renú A, et al. The future of neuroprotection in stroke. J Neurol Neurosurg Psychiatry 2021; 92:129.</a></li><li><a class="nounderline abstract_t">Neuhaus AA, Couch Y, Hadley G, Buchan AM. Neuroprotection in stroke: the importance of collaboration and reproducibility. Brain 2017; 140:2079.</a></li><li><a class="nounderline abstract_t">Goenka L, Uppugunduri Satyanarayana CR, S SK, George M. Neuroprotective agents in Acute Ischemic Stroke-A Reality Check. Biomed Pharmacother 2019; 109:2539.</a></li><li><a class="nounderline abstract_t">Savitz SI, Baron JC, Fisher M, STAIR X Consortium. Stroke Treatment Academic Industry Roundtable X: Brain Cytoprotection Therapies in the Reperfusion Era. Stroke 2019; 50:1026–1031.</a></li><li><a class="nounderline abstract_t">Paul S, Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Exp Neurol 2021; 335:113518.</a></li><li><a class="nounderline abstract_t">Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 2020; 395:878.</a></li><li><a class="nounderline abstract_t">Chen HS, Cui Y, Li XQ, et al. Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial. JAMA 2022; 328:627.</a></li><li><a class="nounderline abstract_t">Hougaard KD, Hjort N, Zeidler D, et al. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. Stroke 2014; 45:159.</a></li><li><a class="nounderline abstract_t">Pico F, Lapergue B, Ferrigno M, et al. Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke: The RESCUE BRAIN Randomized Clinical Trial. JAMA Neurol 2020; 77:725.</a></li><li><a class="nounderline abstract_t">Blauenfeldt RA, Hjort N, Valentin JB, et al. Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial. JAMA 2023; 330:1236.</a></li><li><a class="nounderline abstract_t">Balami JS, Chen RL, Grunwald IQ, Buchan AM. Neurological complications of acute ischaemic stroke. Lancet Neurol 2011; 10:357.</a></li><li><a class="nounderline abstract_t">Shi Q, Presutti R, Selchen D, Saposnik G. Delirium in acute stroke: a systematic review and meta-analysis. Stroke 2012; 43:645.</a></li><li><a class="nounderline abstract_t">Shaw RC, Walker G, Elliott E, Quinn TJ. Occurrence Rate of Delirium in Acute Stroke Settings: Systematic Review and Meta-Analysis. Stroke 2019; 50:3028.</a></li><li><a class="nounderline abstract_t">Oldenbeuving AW, de Kort PL, Jansen BP, et al. Delirium in the acute phase after stroke: incidence, risk factors, and outcome. Neurology 2011; 76:993.</a></li></ol></div><div id="topicVersionRevision">Topic 1126 Version 79.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31662037" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26696642" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28382611" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Parkinsonism or Other Movement Disorders Presenting as Stroke Mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022637" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22556195" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332632" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early stroke recognition: developing an out-of-hospital NIH Stroke Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900010" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Is this patient having a stroke?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9368551" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408548" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431204" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308619" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19051062" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The hydration influence on the risk of stroke (THIRST) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22974646" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intensive care management of acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158464" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932944" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11588337" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430755" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940959" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The deleterious effect of admission hyperglycemia on survival and functional outcome in patients with intracerebral hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283600" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hyperglycemia predicts poststroke infections in acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16873789" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14757880" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hyperglycemia in acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112043" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12221155" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422707" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hyperglycemia presenting as left middle cerebral artery stroke: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14584488" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : European Stroke Initiative Recommendations for Stroke Management-update 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31334795" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24453023" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Insulin for glycaemic control in acute ischaemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478222" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11823659" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851722" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Heads down: flat positioning improves blood flow velocity in acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24652308" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Optical bedside monitoring of cerebral blood flow in acute ischemic stroke patients during head-of-bed manipulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5660303" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of change of head, limb and body position on cephalic circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/932755" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Positional cerebral ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30580740" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Head Positioning in Acute Stroke: Down but Not Out.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28636854" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cluster-Randomized, Crossover Trial of Head Positioning in Acute Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9442407" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nosocomial infection in an intensive-care unit: identification of risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30321906" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Very early versus delayed mobilisation after stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892679" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9472901" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Combating hyperthermia in acute stroke: a significant clinical concern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297248" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160194" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cooling therapy for acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17258670" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Stroke-unit care for acute stroke patients: an observational follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395609" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effectiveness of primary and comprehensive stroke centers: PERFECT stroke: a nationwide observational study from Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20840380" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Stroke unit care in clinical practice: an observational study in the Florence center of the European Registers of Stroke (EROS) Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29864018" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32324916" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Organised inpatient (stroke unit) care for stroke: network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868727" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15961715" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395604" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stroke centers: proof of concept and the concept of proof.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21996470" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477843" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750435" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Should high blood pressure be lowered in the acute stroke?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606927" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute hypertensive response in patients with stroke: pathophysiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390077" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Management of blood pressure for acute and recurrent stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7289008" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Blood pressure after stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11988609" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Blood pressure and clinical outcomes in the International Stroke Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894898" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of blood pressure levels on case fatality after acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894887" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : How to manage blood pressure in acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16339467" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Time is brain--quantified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30460598" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Early Manipulation of Arterial Blood Pressure in Acute Ischemic Stroke (MAPAS): Results of a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30738649" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581662" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581913" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association between course of blood pressure within the first 24 hours and functional recovery after acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14726553" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24240777" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21316752" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621562" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25465108" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022636" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of Blood Pressure Lowering in Early Ischemic Stroke: Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28264916" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Continuing or Temporarily Stopping Prestroke Antihypertensive Medication in Acute Stroke: An Individual Patient Data Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28264916" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Continuing or Temporarily Stopping Prestroke Antihypertensive Medication in Acute Stroke: An Individual Patient Data Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15797657" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Significance of elevated blood pressure and its management on the short-term outcome of patients with acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849654" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Short-acting nifedipine and risk of stroke in elderly hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087898" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The impact of standardized stroke orders on adherence to best practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17724294" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Statin treatment withdrawal in ischemic stroke: a controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22020026" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614435" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Inpatient statin use predicts improved ischemic stroke discharge disposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21372311" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23345634" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The THRombolysis and STatins (THRaST) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152272" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21216670" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026602" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Selective serotonin reuptake inhibitors for stroke recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30528472" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702334" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702335" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33148815" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The future of neuroprotection in stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28641383" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Neuroprotection in stroke: the importance of collaboration and reproducibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30551514" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Neuroprotective agents in Acute Ischemic Stroke-A Reality Check.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31166683" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Stroke Treatment Academic Industry Roundtable X: Brain Cytoprotection Therapies in the Reperfusion Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33144066" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32087818" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35972485" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24203849" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32227157" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke: The RESCUE BRAIN Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37787796" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21247806" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Neurological complications of acute ischaemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267831" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Delirium in acute stroke: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31554501" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Occurrence Rate of Delirium in Acute Stroke Settings: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307355" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Delirium in the acute phase after stroke: incidence, risk factors, and outcome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
